Immune Thrombocytopenic Purpura Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - ResearchAndMarkets.com

DUBLIN--()--The "Immune Thrombocytopenic Purpura Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Immune Thrombocytopenic Purpura Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Immune Thrombocytopenic Purpura Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Immune thrombocytopenic purpura (ITP), is also called as Idiopathic thrombocytopenic purpura is a disease which leads to excessive bleeding and also results in the development of easy bruises. This condition takes place due to the excessive low platelet counts. Platelets help the blood to clot. The ITP affects both children and adults, the children may recover without treatment but for adults, it takes longer to recover. Other symptoms include bleeding from nose and gums, blood in urine and stools and an abnormally heavy menstrual flow.

The report provides Immune Thrombocytopenic Purpura treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Companies Mentioned

  • Principia Biopharma
  • GlaxoSmithKline plc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Amgen Limited & Amgen Ireland Limited
  • PROTALEX, INC.
  • Argenx
  • Immunomedics, Inc.
  • Sanofi
  • UCB S.A., Belgium
  • ILTOO Pharma
  • Kyowa Hakko Kirin Co., Ltd
  • Dova Pharmaceuticals
  • Syntimmune
  • Momenta Pharmaceuticals
  • CSL
  • GENOSCO INC.
  • Hansa Medical AB

Key Topics Covered:

1. Introduction

2. Disease Overview

3. Executive Summary

4. Market Dynamics

5. Pipeline Analysis/Outlook

6. Company Profiling

For more information about this report visit https://www.researchandmarkets.com/research/vnfxpv/immune?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Hematological Drugs